Cytophage Technologies Ltd.
CPTCF
$0.21
$0.0747.71%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.20% | -18.57% | -41.90% | -21.78% | 5.73% |
| Depreciation & Amortization | -51.69% | 2.92% | 34.37% | -3.34% | 53.54% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.69% | -13.04% | -32.71% | -19.41% | 11.26% |
| Operating Income | 8.69% | 13.04% | 32.71% | 19.41% | -11.26% |
| Income Before Tax | 5.88% | 10.39% | 74.56% | 6.64% | -9.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.88% | 10.39% | 74.56% | 6.64% | -9.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.88% | 10.39% | 74.56% | 6.64% | -9.88% |
| EBIT | 8.69% | 13.04% | 32.71% | 19.41% | -11.26% |
| EBITDA | -6.50% | 9.71% | 36.82% | 23.09% | -5.67% |
| EPS Basic | 17.57% | 13.02% | 76.49% | 25.68% | 12.94% |
| Normalized Basic EPS | 18.28% | 13.21% | 36.49% | 29.71% | 12.26% |
| EPS Diluted | 2.03% | 13.02% | 77.54% | 25.68% | 12.94% |
| Normalized Diluted EPS | 18.28% | 13.21% | 36.49% | 29.71% | 12.26% |
| Average Basic Shares Outstanding | 14.58% | 3.53% | 8.34% | 26.00% | 26.18% |
| Average Diluted Shares Outstanding | 14.58% | 3.53% | 8.34% | 26.00% | 26.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |